美国东部地区经治疗的终末期肾病发病率：1973 - 1979年
The incidence of treated end stage renal disease in the eastern United States: 1973-1979.
作者信息
Sugimoto T, Rosansky S J
出版信息
Am J Public Health. 1984 Jan;74(1):14-7. doi: 10.2105/ajph.74.1.14.
Abstract
Incidence rates of treated end stage renal disease (ESRD) by age, sex, race, and reported primary etiology were analyzed for 20 contiguous Eastern States for the period 1973-1979. For White males and females rates have stabilized at 60 and 40 per million person-years, respectively, since 1977. The incidence rates for Blacks (125 per million person-years in males, and 100 in females in 1979), for hypertensive and diabetic nephropathy patients, and for the 65+ age group continue to increase. Higher incidence rates in males were noted for both races during the entire study period. Blacks had twice as high an incidence of treated ESRD as Whites, primarily due to hypertensive and diabetic nephropathy patients (7 and 2.5 times higher, respectively).
摘要
对1973 - 1979年期间20个相邻东部州按年龄、性别、种族和报告的主要病因分析了接受治疗的终末期肾病（ESRD）发病率。自1977年以来，白人男性和女性的发病率分别稳定在每百万人年60例和40例。黑人（1979年男性为每百万人年125例，女性为100例）、高血压和糖尿病肾病患者以及65岁及以上年龄组的发病率继续上升。在整个研究期间，两个种族的男性发病率都较高。黑人接受治疗的ESRD发病率是白人的两倍，主要是由于高血压和糖尿病肾病患者（分别高出7倍和2.5倍）。
相似文献
1
The incidence of treated end stage renal disease in the eastern United States: 1973-1979.美国东部地区经治疗的终末期肾病发病率：1973 - 1979年
Am J Public Health. 1984 Jan;74(1):14-7. doi: 10.2105/ajph.74.1.14.
2
Revisiting racial differences in ESRD due to ADPKD in the United States.重新审视美国 ADPKD 导致的 ESRD 中的种族差异。
BMC Nephrol. 2019 Feb 14;20(1):55. doi: 10.1186/s12882-019-1241-1.
3
Racial differences in the incidence of end-stage renal disease.终末期肾病发病率的种族差异。
Ethn Health. 1996 Mar;1(1):21-31. doi: 10.1080/13557858.1996.9961767.
4
Trends in the incidence of treated end-stage renal disease secondary to diabetic nephropathy: 1975-1984.1975 - 1984年糖尿病肾病所致终末期肾病治疗发病率的趋势
Am J Kidney Dis. 1986 Oct;8(4):234-8. doi: 10.1016/s0272-6386(86)80031-2.
5
Comparative incidence rates of end-stage renal disease treatment by state.按州划分的终末期肾病治疗的比较发病率
Am J Nephrol. 1990;10(3):198-204. doi: 10.1159/000168081.
6
Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994. Central Kentucky Region of the Southeastern United States IgA Nephropathy DATABANK Project.1975年至1994年肯塔基州中部和东部地区IgA肾病的流行病学。美国东南部肯塔基州中部地区IgA肾病数据库项目。
J Am Soc Nephrol. 1998 May;9(5):853-8. doi: 10.1681/ASN.V95853.
7
The Medicare experience with end-stage renal disease: trends in incidence, prevalence, and survival.医疗保险在终末期肾病方面的情况：发病率、患病率及生存率的趋势
Health Care Financ Rev. 1984 Spring;5(3):69-88.
8
The excess risk of treated end-stage renal disease in blacks in the United States.美国黑人中接受治疗的终末期肾病的额外风险。
J Am Soc Nephrol. 1993 Jun;3(12):1961-71. doi: 10.1681/ASN.V3121961.
9
End-stage renal disease in US minority groups.美国少数族裔群体中的终末期肾病
Am J Kidney Dis. 1992 May;19(5):397-410. doi: 10.1016/s0272-6386(12)80945-0.
10
Characteristics of patients referred for treatment of end-stage renal disease in a defined population.特定人群中因终末期肾病接受治疗的患者特征。
Am J Public Health. 1982 Aug;72(8):829-33. doi: 10.2105/ajph.72.8.829.
引用本文的文献
1
Factors affecting the availability and use of hemodialysis facilities.影响血液透析设施可及性和使用情况的因素。
Health Care Financ Rev. 1991 Winter;13(2):49-55.
2
End state renal disease: how many, how much?终末期肾病：多少例，多少量？
Am J Public Health. 1984 Jan;74(1):4-5. doi: 10.2105/ajph.74.1.4.
3
The pathogenesis and prevention of diabetic nephropathy.糖尿病肾病的发病机制与预防
West J Med. 1986 Aug;145(2):222-7.
4
Group participation and survival among patients with end-stage renal disease.终末期肾病患者的群体参与度与生存率
Am J Public Health. 1986 Jun;76(6):670-2. doi: 10.2105/ajph.76.6.670.
5
The epidemiology of end-state renal disease: the six-year South-Central Los Angeles experience, 1980-85.终末期肾病的流行病学：1980 - 1985年洛杉矶中南部地区的六年经验
Am J Public Health. 1987 Jul;77(7):864-5. doi: 10.2105/ajph.77.7.864.
6
Ten Tanzanian transplants: problems and perspectives.十例坦桑尼亚移植手术：问题与展望
Postgrad Med J. 1988 Oct;64(756):778-82. doi: 10.1136/pgmj.64.756.778.
7
Epidemiologic features of treated end-stage renal disease in a large prepaid health plan.大型预付健康计划中接受治疗的终末期肾病的流行病学特征。
Am J Public Health. 1990 Jan;80(1):47-9. doi: 10.2105/ajph.80.1.47.
8
The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans.糖尿病对人体药代动力学和药效学的影响。
Clin Pharmacokinet. 1991 Jun;20(6):477-90. doi: 10.2165/00003088-199120060-00004.
9
End-stage renal disease and race: an overview and perspective.终末期肾病与种族：概述与展望
J Natl Med Assoc. 1991 Sep;83(9):794-8.
本文引用的文献
1
Renal rehabilitation--where are the data?肾脏康复——数据在哪里？
N Engl J Med. 1981 Feb 5;304(6):351-2. doi: 10.1056/NEJM198102053040609.
2
The impact of heroin abuse on a regional end-stage renal disease program.海洛因滥用对某地区终末期肾病项目的影响。
Am J Public Health. 1980 Aug;70(8):829-31. doi: 10.2105/ajph.70.8.829.
3
Treatment of end-stage renal disease: free but not equal.终末期肾病的治疗：免费但不平等。
N Engl J Med. 1980 Oct 23;303(17):996-8. doi: 10.1056/NEJM198010233031708.
4
Complications of dialysis.透析的并发症。
Clin Nephrol. 1981 Feb;15(2):66-74.
5
Racial differences in the incidence of treatment for end-stage renal disease.终末期肾病治疗发生率的种族差异。
N Engl J Med. 1982 May 27;306(21):1276-9. doi: 10.1056/NEJM198205273062106.
6
Implications for health care policy. A social and demographic profile of hemodialysis patients in the United States.对医疗保健政策的影响。美国血液透析患者的社会和人口统计学概况。
JAMA. 1981 Feb 6;245(5):487-91. doi: 10.1001/jama.245.5.487.
7
Medicare end-stage renal disease program: more than a billion dollar question.医疗保险终末期肾病项目：超十亿美元的问题
Ann Intern Med. 1980 Sep;93(3):501-2. doi: 10.7326/0003-4819-93-3-501.
8
Prevalence of chronic renal failure and access to dialysis.慢性肾衰竭的患病率及透析可及性。
Int J Epidemiol. 1973 Autumn;2(3):247-55. doi: 10.1093/ije/2.3.247.
9
Racial factors in the incidence and causation of end-stage renal disease (ESRD).终末期肾病（ESRD）发病率及病因中的种族因素。
Trans Am Soc Artif Intern Organs. 1977;23:28-33. doi: 10.1097/00002480-197700230-00008.
10
Characteristics of Connecticut patients receiving services for end-stage uremia.接受终末期尿毒症治疗服务的康涅狄格州患者的特征。
Public Health Rep. 1975 Sep-Oct;90(5):440-8.
Zotero 插件